The Ipamorelin Ghrelin Receptor refers to the Growth Hormone Secretagogue Receptor type 1a (GHSR-1a), which is the specific molecular target for the synthetic peptide Ipamorelin. Ipamorelin acts as a selective agonist at this receptor, mimicking the action of the endogenous hormone ghrelin. Activating this receptor is a pharmaceutical strategy used to stimulate the pituitary gland’s natural release of growth hormone without significantly affecting cortisol or prolactin levels.
Origin
The term combines the name of the synthetic secretagogue, Ipamorelin, with its natural target, the ghrelin receptor, which was discovered in the late 1990s. This receptor system is rooted in the discovery of ghrelin as the body’s only known circulating appetite-stimulating hormone and a potent growth hormone secretagogue. Ipamorelin represents a refinement of this pharmacological class.
Mechanism
Ipamorelin binds to the GHSR-1a receptor, which is highly concentrated in the pituitary and hypothalamus, causing a conformational change that initiates intracellular signaling cascades. This binding stimulates the somatotroph cells in the anterior pituitary to release growth hormone in a natural, pulsatile manner. Crucially, Ipamorelin is highly selective for GH release, avoiding the unwanted side effects on cortisol and appetite stimulation often associated with other ghrelin mimetics.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.